Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Summary
Climb Bio reported initial Phase 1b data for budoprutug in immune thrombocytopenia at the EHA Congress 2026. The company said the antibody showed a favorable safety profile, strong B-cell depletion, and encouraging platelet responses in heavily pretreated patients. Enrollment continues in the highest-dose cohort, and Climb Bio expects more data later in 2026. The update supports ongoing clinical development of budoprutug across multiple autoimmune indications.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected